Lupin Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Aurangabad facility (classified as CSN - Cumulative Site Network), following the regulator's inspection concluded earlier. An EIR is formally issued by the FDA after it completes an audit of a drug manufacturing site and generally indicates that the inspection has been officially closed, typically with a satisfactory or acceptable classification. The facility is one of Lupin's key manufacturing units supplying generic formulations to the U.S. market, and clearance here removes a regulatory overhang on that site. The announcement is based on a press release dated November 12, 2025.
Positive for shareholders — the EIR signals satisfactory regulatory standing for the Aurangabad plant, allowing uninterrupted U.S. supplies and reducing compliance risk. Could support sentiment around Lupin's U.S. business, though investors should watch for details on the inspection classification (VAI/OAI).